ClexBio
ClexBio has developed a proprietary biological platform that enables stem cell therapies to function safely in solid tissues. Our lead program, a liver implant for acute liver failure, has demonstrated strong preclinical function and durability. We are advancing toward IND-enabling studies and building strategic partnerships with biopharma to expand into additional indications such as type 1 diabetes and cardiac repair. We have a $10M round ongoing - term sheet secured.
Date, time and room information
Tuesday, May 5, 15:00 - 15:15, room Singapore
Category
Emerging biotech company
Title of the presentation
Unlocking Stem Cell Therapy for Solid Organs
Speaker information
| Name | Position | Institution |
|---|---|---|
| Armend Hati | CEO & co-founder | ClexBio |
Host and event manager:
Logistics and marketing partner:
